Neuroleptic malignant syndrome
- 1 September 1986
- journal article
- research article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 80 (3) , 171-178
- https://doi.org/10.1080/00325481.1986.11699520
Abstract
Preview The neuroleptic malignant syndrome (NMS) is an idiosyncratic reaction to neuroleptic agents that consists of fever, mental status changes, muscle rigidity, autonomic dysfunction, respiratory distress, and rhabdomyolysis. This potentially lethal disease is not widely recognized and is probably underdiagnosed, but early recognition and therapy may decrease morbidity and mortality. The authors summarize the major features of NMS and review supportive therapy and specific investigational treatment with anticholinergics, muscle relaxants, and dopamine agonists. They also offer guidelines for restarting therapy with neuroleptics in patients recovering from NMS.Keywords
This publication has 10 references indexed in Scilit:
- Neuroleptic Malignant SyndromeJAMA, 1985
- Bioavailability of Oral PhysostigmineNew England Journal of Medicine, 1985
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985
- Neuroleptic malignant syndromeAmerican Journal of Psychiatry, 1985
- Neuroleptic malignant syndromePsychosomatics, 1985
- Neuroleptic Malignant SyndromeNew England Journal of Medicine, 1985
- Case report of neuroleptic malignant syndrome associated with withdrawal from amantadineAmerican Journal of Psychiatry, 1984
- The Neuroleptic Malignant SyndromeArchives of internal medicine (1960), 1982
- Neuroleptic Malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington diseaseNeurology, 1981
- Die tödliche KatatonieArchiv Fur Psychiatrie Und Nervenkrankheiten, 1934